Founded with a mission to revolutionize medical imaging, Pymedix focuses on developing fully-automated machine perception technologies. Their core product, Autofuse, is a 3D deformable image registration software designed to enhance the accuracy and speed of radiotherapy, enabling more personalized cancer treatment. By integrating cross-disciplinary expertise, Pymedix aims to advance the radiotherapy experience and improve patient outcomes in the medical imaging market.

Pymedix has garnered attention for its innovative approach and has attracted notable investors and experts in the field of medical imaging and radiotherapy. The company's achievements include significant advancements in image registration technology, setting new standards for accuracy and efficiency in cancer treatment. Pymedix's impact is reflected in its potential to transform how radiotherapy is administered, offering hope for better patient care and outcomes.